| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) – |
| 26 Oct 2026 |
8-K: Results of Operations and Financial Condition
Estimated Q3 Financial Impacts Related to the Actio Biosciences, Inc. Acquisition |
| 09 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company”), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier ... |
| 23 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
This AMENDMENT No. 4, dated as of September 23, 2026 (this “Amendment”), to the Credit Agreement, dated as of May 5, 2021 (as amended by that certain LIBOR Successor Rate Conforming Changes Amendment, dated as of June 7, 2023, that certa... |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy |
| 31 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
INDENTURE, dated as of August 31, 2026 by and among Jazz Investments I Limited, a Bermuda exempted company limited by shares, as Issuer (as more fully set forth in Section 1.01, the “Issuer”), Jazz Pharmaceuticals Public Limited Company,... |
| 25 Aug 2026 |
8-K: Other Events
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma |
| 10 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
Certain confidential information contained in this exhibit has been omitted by means of redacting a portion of the text and replacing it with [***], pursuant to Regulation S-K Item 601(b) of the Securities Act of 1933, as amended. Certai... |
| 10 Aug 2026 |
8-K: Regulation FD Disclosure
Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) – |
| 24 Jul 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On July 23, 2026, Jazz Pharmaceuticals plc (the “Company”) held its 2026 annual general meeting of shareholders (the “Annual Meeting”), at the Company’s corporate headquarters located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dub... |
| 29 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for r... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
– Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition
– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 – |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
January 2026 44th Annual J.P. Morgan Healthcare Conference Redefining Possibilities in Rare Disease Renee Gala, President & CEO |
| 17 Nov 2025 |
8-K: Other Events
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesopha... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
– Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG – |
| 28 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 23, 2025, the board of directors (the “Board”) of Jazz Pharmaceuticals plc (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Ted Love to the Board, effect... |
| 22 Oct 2025 |
8-K: Other Events
On October 21, 2025, Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Ltd., subsidiaries of Jazz Pharmaceuticals plc (collectively, the “Company”) entered into a global settlement agreement (the “Settlement Agreement”) with Av... |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
– Renee Gala named as President and CEO, effective August 11 – |
Loading...